CF
VRTX icon

Centaurus Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Centaurus Financial’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22M Sell
2,721
-215
-7% -$100K 0.06% 298
2025
Q4 		$1.33M Sell
2,936
-91
-3% -$39.2K 0.06% 279
2025
Q3 		$1.19M Buy
3,027
+655
+28% +$274K 0.06% 292
2025
Q2 		$1.06M Buy
2,372
+61
+3% +$28.1K 0.06% 291
2025
Q1 		$1.12M Buy
2,311
+316
+16% +$147K 0.07% 261
2024
Q4 		$803K Buy
1,995
+137
+7% +$63.5K 0.05% 310
2024
Q3 		$864K Buy
1,858
+289
+18% +$139K 0.06% 290
2024
Q2 		$735K Buy
1,569
+136
+9% +$59K 0.05% 299
2024
Q1 		$599K Buy
1,433
+852
+147% +$360K 0.04% 351
2023
Q4 		$236K Buy
581
+116
+25% +$42.9K 0.02% 547
2023
Q3 		$162K Buy
465
+81
+21% +$28.3K 0.01% 617
2023
Q2 		$135K Sell
384
-71
-16% -$23.9K 0.01% 663
2023
Q1 		$143K Buy
455
+47
+12% +$14.1K 0.01% 756
2022
Q4 		$118K Sell
408
-48
-11% -$14.6K 0.01% 743
2022
Q3 		$132K Buy
456
+98
+27% +$28.2K 0.01% 729
2022
Q2 		$101K Buy
+358
New +$95.8K 0.01% 805
2021
Q2 		– Sell
-3,754
Closed -$807K – 937
2021
Q1 		$807K Sell
3,754
-756
-17% -$166K 0.08% 275
2020
Q4 		$1.07M Buy
4,510
+137
+3% +$31.4K 0.11% 216
2020
Q3 		$1.19M Sell
4,373
-53
-1% -$14.6K 0.16% 145
2020
Q2 		$1.28M Buy
4,426
+3,177
+254% +$861K 0.19% 139
2020
Q1 		$297K Buy
1,249
+21
+2% +$4.82K 0.06% 268
2019
Q4 		$269K Buy
+1,228
New +$249K 0.04% 395
2018
Q3 		– Sell
-235
Closed -$40K – 2003
2018
Q2 		$40K Buy
+235
New +$36.4K 0.01% 1032

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Centaurus Financial's VRTX Position: Q1 2026 in Review

Centaurus Financial reduced its Vertex Pharmaceuticals (VRTX) stake by 7.3% in Q1 2026, selling an estimated $100K and leaving 2,721 shares worth $1.22M. The position accounts for 0.06% of the portfolio, ranked #298.

Centaurus Financial first reported a position in VRTX in Q2 2018 and has held it in 23 quarters since. The position peaked at $1.33M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Centaurus Financial held 2,721 shares of Vertex Pharmaceuticals worth $1.22M as of Q1 2026.
  • Centaurus Financial sold 215 Vertex Pharmaceuticals shares in Q1 2026, an estimated $100K.
  • Vertex Pharmaceuticals made up 0.06% of Centaurus Financial's portfolio in Q1 2026, its #298 holding.
  • Centaurus Financial first reported a position in Vertex Pharmaceuticals in Q2 2018 and has held it in 23 quarters since.
  • Centaurus Financial's Vertex Pharmaceuticals position peaked at $1.33M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.